Drug ID: 1d00000119
Drug Name: Arformoterol Tartrate
Generic Names: Deriform Resp
Category: Anti- Asthmatics
Legal Status: Non Opioid Prescription only drug
Indication for Mother: Category C
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Recommended Dose: The recommended dose is one 15-mcg unit-dose vial administered twice daily (morning and evening).
Recommended In: This medication is a long-acting beta-agonist bronchodilator, prescribed for chronic obstructive pulmonary disease (COPD).
Directions For Use: It comes as a nebulizer for oral inhalation.
Storage: Store the medication as directed by your physician.
Dosage Forms: Inhalation nebulizer
Side Effects: Body as a Whole - Abscess, allergic reaction, digitalis intoxication, fever, hernia, injection site pain, neck rigidity, neoplasm, pelvic pain and retroperitoneal hemorrhage.
Heart - Blood clots in veins, abnormal heart rhythm, congestive heart failure, heart block, heart attack, prolonged QT interval and fast heart rate.
Gastrointestinal - Constipation, stomach inflammation, blood in stool, mouth infection, periodontal abscess and rectal bleeding.
Metabolic - Dehydration, fluid renetention, decreased glucose tolerance levels, gout, increase or decrease in blood glucose.
Musculoskeletal - Joint pain/inflammation, bone disorder, rheumatoid arthritis.
Central Nervous System - Agitation, stroke, decreased body movement, paralysis, drowsiness and tremor.
Respiratory - Lung cancer, respiratory disorder and voice alteration.
Skin - Dry skin, herpes simplex, herpes zoster, skin discoloration and skin hypertrophy.
Eye - Abnormal vision and glaucoma.
Genitourinary - Breast cancer, calcium crystalluria (presence of calcium phosphate crystals in urine sediment), blood in urine, kidney stone, night time urination, increase PSA levels, pus in urine, urinary tract disorder and urine abnormality.
In Case of Overdose: Signs and symptoms may include angina, hypertension or hypotension, tachycardia, with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of Arformoterol Tartrate Inhalation Solution.
Treatment of overdosage consists of discontinuation of Arformoterol Tartrate Inhalation Solution together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Arformoterol Tartrate Inhalation Solution. Cardiac monitoring is recommended in cases of overdosage.
Avoid If: Caution should be exercised in patients with history of history of other breathing problems (eg, asthma), diabetes, heart or liver disease, high blood pressure, low blood potassium levels, seizures, overactive thyroid, irregular heartbeat, overexcitement, who are taking or have taken monoamine oxidase inhibitor (MAOI) within the last 14 days, any allergy, during pregnancy and breastfeeding.
It may cause dizziness, do not drive a car or operate machinery while taking this medication.
Monitor blood sugar, lung function and blood potassium levels regularly while taking this medication.
Contraindicated in patients with asthma, and hypersensitivity.
Drug Interaction: Adrenergic Drugs
If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of arformoterol may be potentiated.
Xanthine Derivatives, Steroids, Or Diuretics
Concomitant treatment with methylxanthine (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists including arformoterol Inhalation Solution.
Non-potassium Sparing Diuretics
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists, including arformoterol Inhalation Solution, with non-potassium sparing diuretics.
MAO Inhibitors, Tricyclic Antidepressants, QTc Prolonging Drugs
arformoterol Inhalation Solution, as with other beta-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because of the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.
Beta-adrenergic receptor antagonists (beta-blockers) and arformoterol Inhalation Solution may inhibit the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.